hepatocellular carcinoma (HCC), has grown by 25-30% in the past two decades, with much of the growth attributed to the dramatic rise in fatty liver disease, which currently affects 25% of adult ...

The Italian study showed that patients with HCC resulting from viral infections or fatty liver had significantly higher ...

The risk of dying from the most common form of primary liver cancer is about 30% higher for patients with low household ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Hepatocellular carcinoma (HCC) is a common malignant tumor and the third leading cause of cancer-related mortality. The lack ...

Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given the increased risk of death from cirrhosis-related complications in patients ...

Industry Giants Gilead Sciences, Bristol Myers Squibb, AbbVie, and Merck & Co. Lead the CompetitionDublin, May 06, 2025 (GLOBE NEWSWIRE) -- The "Liver Disease Treatments Market" report has been added ...

By analysing DNA from blood samples, Tvaster Genkalp is working to make cancer diagnostics more accessible, accurate, and ...

University of Kentucky Markey Cancer Center researchers have identified a mechanism by which a gut hormone contributes to ...

Strategic insight into the Liver Cancer Treatment Market reveals a high-growth opportunity, especially in Asia-Pacific, driven by a rising patient po ...